UK markets open in 7 hours 48 minutes

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,243.00+18.80 (+1.54%)
At close: 4:38PM GMT
Full screen
Previous close1,224.20
Open1,212.40
Bid1,225.60 x 0
Ask1,250.00 x 0
Day's range1,210.80 - 1,247.00
52-week range1,190.80 - 1,772.51
Volume9,846,843
Avg. volume10,424,329
Market cap62.536B
Beta (5Y monthly)0.35
PE ratio (TTM)10.89
EPS (TTM)114.10
Earnings date28 Apr 2021
Forward dividend & yield0.80 (6.44%)
Ex-dividend date18 Feb 2021
1y target est1,644.50
  • Motley Fool

    After 2 Licensing Deals Will GlaxoSmithKline Acquire Vir?

    Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet.

  • Motley Fool

    Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

    Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.

  • Motley Fool

    Will Sanofi and GlaxoSmithKline Be Too Late to the Party With Their COVID Vaccine?

    Johnson & Johnson (NYSE: JNJ) recently won U.S. Emergency Use Authorization (EUA) for its vaccine. In this Motley Fool Live video, recorded on Feb. 24, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not Sanofi and GlaxoSmithKline might be too late to the party.